Most Read Articles
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.

ADHD medication poses no increased seizure risk in epilepsy

12 Feb 2019

Use of attention‐deficit/hyperactivity disorder (ADHD) medication does not contribute to an increased risk of seizure in patients with epilepsy, a study suggests.

The study included 21,557 individuals with a seizure history, of whom 6,773 were <19 years of age and met the criteria for epilepsy and 1,605 of these were receiving continuous antiepileptic drug (AED) treatment. Conditional Poisson regression facilitated comparison of the seizure rate during the 24 weeks before and after initiation of ADHD medication with the rate during the same 48 weeks in the previous year, whereas Cox regression was used to compare the seizure rate during ADHD medication periods with the rate during nonmedication periods.

A total of 995 individuals initiated ADHD medication during follow‐up. In this group, the rate of seizure risk did not significantly differ during the 24 weeks before and after medication initiation (83 events in 57 individuals) relative to the same period in the previous year (82 events in 60 individuals).

In the entire cohort, 11,754 seizure events occurred during 136,846 person‐years, and 1,855 individuals had at least one ADHD medication period. Compared with nonmedication periods, ADHD medication periods were associated with a 27-percent lower rate of acute seizures (hazard ratio, 0.73; 95 percent CI, 0.57–0.94).

Associations were similar in young people with epilepsy and continuous AED treatment.

Overall, the findings suggest that epilepsy should not automatically preclude patients from receiving ADHD medications, researchers said.

The present study has important clinical implications given that ADHD is commonly diagnosed in childhood or adolescence—although concerns about pharmaceutical treatment of ADHD in individuals with epilepsy are not limited to childhood—and clinical decisions regarding treatment initiation may be especially challenging in children with active epilepsy, they pointed out.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.